RecruitingPhase 4NCT07503652
Clinical Observation of Xeligekimab in the Treatment of Moderate to Severe Palmoplantar Pustulosis
Studying Pustulosis palmaris et plantaris
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- First Hospital of China Medical University
- Intervention
- Xeligekimab Injection(drug)
- Enrollment
- 10 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2026 – 2027
Study locations (1)
- First Hospital of China Medical University, Shenyang, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07503652 on ClinicalTrials.govOther trials for Pustulosis palmaris et plantaris
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE4NCT07513142PPP Versus Corticosteroid for Thigh Muscle InjuriesAndrews Research & Education Foundation
- RECRUITINGPHASE3NCT07219420A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar PustulosisUCB Biopharma SRL
- RECRUITINGNANCT07270003A Prospective, Single-arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Ivarmacitinib in the Treatment of Palmoplantar PustulosisXijing Hospital
- RECRUITINGPHASE2NCT07013201A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar PustulosisLEO Pharma